Development and evaluation of a novel series of Nitroxoline-derived BET inhibitors with antitumor activity in renal cell carcinoma

Small molecular inhibitors targeting BRD4 family proteins are emerging as promising therapies in many types of human malignancies. However, whether BRD4, as well as other BET family members, may serve as therapeutic targets in renal cell carcinoma (RCC) remains unknown. In this study, we found that...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Wei, Zhang, Hao, Chen, Zhifeng, Jiang, Hao, Liao, Liping, Fan, Shijie, Xing, Jing, Xie, Yiqian, Chen, Shijie, Ding, Hong, Chen, Kaixian, Jiang, Hualiang, Luo, Cheng, Zheng, Mingyue, Yao, Zhiyi, Huang, Yiran, Zhang, Yuanyuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6212493/
https://www.ncbi.nlm.nih.gov/pubmed/30385738
http://dx.doi.org/10.1038/s41389-018-0093-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6212493/
https://www.ncbi.nlm.nih.gov/pubmed/30385738
http://dx.doi.org/10.1038/s41389-018-0093-z

Ejemplares similares